42C — IX Biopharma Share News
0.000.00%
- SG$376.80m
- SG$366.21m
- SG$7.77m
Brief: IX Biopharma To Issue 1 MLN New Shares To Anson Properties At S$0.4215 Per Share
Brief: IX Biopharma Says US Government Awards US$41 MLN Contract To Fund Development Of Wafermine
Brief: IX Biopharma To Raise At Least S$6 MLN Via Placement At S$0.198 Per Share
Brief: IX Biopharma Enters Term Sheet For Proposed Joint Venture
Brief: IX Biopharma Proposes Placement To Raise No Less Than S$5 Million
Brief: IX Biopharma Announces Termination Of Wafermine Licensing Agreement
Brief: IX Biopharma Posts HY Revenue S$2.7 Million
Brief: Ix Biopharma Says Notice Of Termination Of Wafermine Licensing Agreement
Brief: Ix Biopharma Unveils Development Of Interferon Wafer To Combat Respiratory Viral Diseases
Brief: IX Biopharma Says Issuance Of Convertible Bonds Of About Of S$2 Mln
Brief: IX Biopharma Proposes Placement Of 13.7 Million New Ordinary Shares
Brief: IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics
Brief: IX Biopharma Says Entered Agreement With China Resources Pharmaceutical Commercial Via Unit
Brief: Ix Biopharma HY Loss S$5.4 Million Versus Loss Of S$4.7 Million
Brief: IX Biopharma's Through Unit Enters Deal With Organic Genetics Group
Brief: IX Biopharma Says Exploring Possibility Of A Spin-Off Of Its Pharmaceutical Business
Brief: IX Biopharma Obtained Export Listing Status For Xativa
Brief: IX Biopharma Proposes Renounceable Non-Underwritten Rights Issue
Brief: IX Biopharma Set To Expand Its Current Wafer Production Capacity At Facility In Australia